bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials

bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials

This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessment method (CRM) designs in Phase I dose-escalation trials. CRM designsare a class of adaptive design that select the dose to be given to the next recruited patient based on accumulating toxicity data f...

Full description

Bibliographic Details
Main Authors:	Michael Sweeting, Adrian Mander, Tony Sabin
Format:	Article
Language:	English
Published:	Foundation for Open Access Statistics 2013-09-01
Series:	Journal of Statistical Software
Online Access:	http://www.jstatsoft.org/index.php/jss/article/view/2093

Similar Items

How to design a dose-finding study using the continual reassessment method
by: Graham M. Wheeler, et al.
Published: (2019-01-01)

A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies
by: Niansheng Tang, et al.
Published: (2018-12-01)

A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research
by: Chunyan Cai, et al.
Published: (2017-09-01)

Poverty reduction strategies in Blue Crane Route Municipality (BCRM)
by: Twenty, Isaac Lungisa
Published: (2015)

Two-stage Continual Reassessment Method and Patient Heterogeneity for Dose-finding Studies
by: Jia, Xiaoyu
Published: (2014)

A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method
by: Bernard North, et al.
Published: (2019-06-01)

A web tool for designing and conducting phase I trials using the continual reassessment method
by: Nolan A. Wages, et al.
Published: (2018-02-01)

AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials.
by: Graham M Wheeler, et al.
Published: (2016-01-01)

Bayesian Adaptive Dose-Finding Clinical Trial Designs with Late-Onset Outcomes
by: Zhang, Yifei
Published: (2021)

The continual reassessment method for multiple toxicity grades: a bayesian model selection approach.
by: Haitao Pan, et al.
Published: (2014-01-01)

Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies
by: G. D. James, et al.
Published: (2021-01-01)

Bayesian Two-Stage Designs for Phase II Clinical Trials with Continuous Endpoints
by: Chen, Szu-Hsuan, et al.
Published: (2013)

A Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis
by: Whitehead Anne, et al.
Published: (2011-12-01)

The Bayesian analysis of dose titration to effect in phase 2 clinical trials in order to design phase 3
by: Bedding, Alun W.
Published: (2008)

Bayesian reassessment of the epigenetic architecture of complex traits
by: Daniel Trejo Banos, et al.
Published: (2020-06-01)

A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar.
by: James A Watson, et al.
Published: (2020-11-01)

Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents.
by: Christophe Le Tourneau, et al.
Published: (2012-01-01)

Determination of the ED95 of intrathecal hyperbaric prilocaine with sufentanil for scheduled cesarean delivery: a dose-finding study based on the continual reassessment method
by: P. Goffard, et al.
Published: (2020-11-01)

BOIN: An R Package for Designing Single-Agent and Drug-Combination Dose-Finding Trials Using Bayesian Optimal Interval Designs
by: Fangrong Yan, et al.
Published: (2020-09-01)

The flexible bivariate continual reassessment method
by: Thomann, Mitchell Alan
Published: (2015)

Bayesian optimization for estimating the maximum tolerated dose in Phase I clinical trials
by: Ami Takahashi, et al.
Published: (2021-03-01)

Author Correction: Bayesian reassessment of the epigenetic architecture of complex traits
by: Daniel Trejo Banos, et al.
Published: (2020-10-01)

A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades
by: Márcio A. Diniz, et al.
Published: (2020-07-01)

Comparison between continuous and discrete doses for model based designs in cancer dose finding.
by: Márcio Augusto Diniz, et al.
Published: (2019-01-01)

A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations in the Presence of a Baseline Covariate
by: Márcio Augusto Diniz, et al.
Published: (2018-01-01)

Semi-parametric bayesian model, applications in dose finding studies
by: Clertant, Matthieu
Published: (2016)

Bayesian test-based designs for phase I clinical trials
by: Chia-Ru Chung, et al.
Published: (2017)

Implementing the EffTox dose-finding design in the Matchpoint trial
by: Kristian Brock, et al.
Published: (2017-07-01)

On the coherence of model-based dose-finding designs for drug combination trials.
by: Yeonhee Park, et al.
Published: (2020-01-01)

Reassessing the Reassessment of suPAR in glomerular disease
by: Björn eMeijers, et al.
Published: (2015-01-01)

Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples
by: Erik van Werkhoven, et al.
Published: (2020-06-01)

TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis
by: M. Cole, et al.
Published: (2021-07-01)

A reassessment of the production of acetone and butanol by Clostridium acetobutylicum in continuous culture
by: Clarke, Kim Gail
Published: (2016)

Modified one-stage continual reassessment method with asymmetric loss function
by: Chen-YuLin, et al.
Published: (2013)

Bayesian Design in Clinical Trials
Published: (2022)

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial
by: Diane Pannier, et al.
Published: (2018-07-01)

Reassessment of Gene-Elusive Familial Dilated Cardiomyopathy Leading to the Discovery of a Homozygous AARS2 Variant—The Importance of Regular Reassessment of Genetic Findings
by: Priya Bhardwaj, et al.
Published: (2021-07-01)

Bayesian Approaches for design and evaluation of the Phase II clinical trials incorporating safety and the multiregional clinical trials
by: Cheng, Yu-Chieh, et al.
Published: (2017)

Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials.
by: Dominic Magirr, et al.
Published: (2016-01-01)

Rethinking remdesivir for COVID-19: A Bayesian reanalysis of trial findings.
by: Joyce M Hoek, et al.
Published: (2021-01-01)